Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin with R-DHAP in CD30+ DLBCL
NCT03356054Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Mar 2018
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoints: Rate of patients with serious toxicity during cycle 1-2 at 6 weeks, Metabolic Complete Response Rate at 9 weeks and 1 more. Started Mar 2018; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03356054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356054.